Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.32 USD | -1.49% | -10.20% | +30.69% |
May. 15 | Canaccord Genuity Trims Price Target on Passage Bio to $13 From $14, Maintains Buy Rating | MT |
Mar. 04 | Passage Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 81.33M |
---|---|---|---|---|---|
Net income 2024 * | -69M | Net income 2025 * | -82M | EV / Sales 2024 * | - |
Net cash position 2024 * | 59.7M | Net cash position 2025 * | - | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-1.23
x | P/E ratio 2025 * |
-1.97
x | Employees | 58 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.51% |
Latest transcript on Passage Bio, Inc.
1 day | -1.49% | ||
1 week | -10.20% | ||
Current month | +2.33% | ||
1 month | +3.94% | ||
3 months | +1.93% | ||
6 months | +120.00% | ||
Current year | +30.69% |
Managers | Title | Age | Since |
---|---|---|---|
William Chou
CEO | Chief Executive Officer | 51 | 22-10-09 |
James M. Wilson
FOU | Founder | - | 17-06-30 |
Director of Finance/CFO | 48 | 21-10-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Maxine Gowen
CHM | Chairman | 66 | 21-02-17 |
Saqib Islam
BRD | Director/Board Member | 54 | 19-03-28 |
Director/Board Member | 52 | 20-01-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 2 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-05-17 | 1.32 | -1.49% | 38,644 |
24-05-16 | 1.34 | +4.69% | 117,807 |
24-05-15 | 1.28 | -3.40% | 71,668 |
24-05-14 | 1.325 | -10.47% | 131,504 |
24-05-13 | 1.48 | +0.68% | 32,392 |
Delayed Quote Nasdaq, May 17, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+30.69% | 81.33M | |
+9.42% | 115B | |
+11.84% | 106B | |
-1.05% | 21.96B | |
-14.15% | 21.84B | |
-5.29% | 19.21B | |
-4.16% | 18.08B | |
-38.29% | 17.71B | |
+7.99% | 14.32B | |
+36.24% | 12.42B |
- Stock Market
- Equities
- PASG Stock